Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

A Double-Barreled Payoff

Early Friday, we told you that Enanta Pharmaceuticals Inc. (NasdaqGS: ENTA) was demonstrating immunity to the recent stock-market sell-off.

When the market opened later that morning, shares of the biotech jumped more than 18% because of an upbeat report about the late-state trial on the oral Hepatitis C (HCV) drug that AbbVie Inc. (NYSE: ABBV) is developing using Enanta's "protease inhibitor" technology.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK